Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777872 | 0.85 | ACHE (0.37) | ACHENFE2L2 | |
| SCHEMBL7937933 | 0.82 | ACHE (0.34) | ACHENFE2L2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL514390 | 0.81 | ACHE (0.42) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL4127092 | 0.80 | ACHE (0.37) | ACHECES2CES1TAAR1GAA | |
| SCHEMBL16269560 | 0.80 | ACHE (0.39) | ACHENFE2L2GAASMN1; SMN2 | |
| SCHEMBL3207396 | 0.79 | ACHE (0.50) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL31005130 | 0.79 | ACHE (0.50) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL777916 | 0.79 | CES2 (0.38) | CES2CES1 | |
| SCHEMBL2460604 | 0.79 | ACHE (0.40) | ACHENFE2L2CES2CES1TAAR1 | |
| SCHEMBL18195202 | 0.79 | ACHE (0.40) | ACHENFE2L2CES2CES1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132782-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. | 2023-05-04 | — | — | US | claimed |
| EP-4121040-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | Global Biolife Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2021188520-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-8034838-B2 | Composition and method for the treatment of neurological disorders | GLOBAL BIOLIFE, INC. | 2011-10-11 | — | — | US | claimed |
| US-20090298932-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLOBAL BIOLIFE, INC. | 2009-12-03 | — | — | US | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20230132782-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4121040-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | Global Biolife Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| CN-108430613-B | Zwitterionic sulfone polymer blend and hollow fiber membranes | 思拓凡瑞典有限公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021188520-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | GLOBAL BIOLIFE INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
| US-6054501-A | CURABILITY; GLOSSINESS; CAN BE BLENDED WITH INKS, PAINTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2000-04-25 | — | — | US | disclosed |
| EP-0844255-A1 | PHOTOPOLYMERIZATION INITIATOR AND ACTINIC RADIATION-CURABLE COMPOSITION COMPRISING THE SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0629613-B1 | Novel onium salt, photopolymerization initiator, energy ray-curing composition containing the initiator, and cured product | NIPPON KAYAKU KK (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5534557-A | COATINGS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-07-09 | — | — | US | disclosed |
| US-5502083-A | SULFONIUM CATALYST | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-03-26 | — | — | US | disclosed |
| EP-0629613-A2 | Novel onium salt, photopolymerization initiator, energy ray-curing composition containing the initiator, and cured product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132782-A1 | METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION | ACE2, ACE, TMPRSS2 | ACHE 280/4885NFE2L2 823/4885CES2 332/4885 |
| US-20090298932-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BACE1, APP, BACE2 | ACHE 8/4885NFE2L2 2262/4885CES2 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.